Treatment outcomes for major depressive disorder (MDD) need to be improved. Presently,
no clinically relevant tools have been established for stratifying subgroups or predicting …

Abstract Treatment outcomes for major depressive disorder (MDD) need to be improved.
Presently, no clinically relevant tools have been established for stratifying subgroups or …

Objective: This article presents the case that a more rapid, individualized approach to
treating major depressive disorder (MDD) may increase the likelihood of achieving full …

A2019 meta-analysis that included five randomized control trials (RCTs)(n51, 737)
evaluated the effectiveness of pharmacogenetic-guided treatment of major depressive …

Major depressive disorder (MDD) is frequently unrecognized and underdiagnosed by
clinicians and thus remains untreated or inappropriately treated in routine clinical practice …

Background Pharmacogenomic testing guided treatment have been developed to guide
drug selection or conversion in major depressive disorder patients. Whether patients benefit …

Depression is the single largest contributor to non-fatal health loss and affects 322 million
people globally. The clinical heterogeneity of this disorder shows biological correlates and it …

Background Major depressive disorders (MDD) is a common mental disorder with high
prevalence, frequent relapse and associated with heavy disease burden. Heritability …

Background Pharmacogenomic testing has recently become scalable and available to guide
the treatment of major depressive disorder (MDD). The objective of the current meta-analysis …

The sequencing of the human genome in the early days of this millennium was greeted with
great fanfare as this accomplishment was expected to revolutionize medicine and result in …